Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet

Sanofi is paying Biond Biologics $125 million upfront for global rights to a novel immune checkpoint inhibitor. The agreement gives Sanofi a near-clinical anti-ILT2 monoclonal antibody designed to turn the innate and adaptive immune systems against tumors.